Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587.

The dipyridodiazepinone human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase (RT) inhibitor BI-RG-587 was tested for its ability to inhibit HIV-1 replication in both acutely and chronically infected cell lines. The ability of BI-RG-587 to inhibit steps in the virus replicative cycle other than reverse transcription was also assessed. BI-RG-587 was found to be a potent inhibitor of HIV-1 replication in acutely infected cells (50% inhibitory concentration [IC50] = 37.2 nM), and the sensitivity and kinetics of that inhibition was similar to the known RT inhibitor zidovudine (AZT). Even at 100x IC50, BI-RG-587 had no effect on gp120/CD4 interaction, syncytia formation, or envelope glycoprotein processing. In addition, no inhibition of viral replication or protein production was noted in a chronically infected cell line that produces viral products in an RT-independent manner. Finally, no inhibition of acute HIV-2 replication was noted, even with very high (2500x IC50 for HIV-1) concentrations of BI-RG-587. These results demonstrate that BI-RG-587 is a potent inhibitor of HIV-1 replication and that this inhibition occurs at the point of reverse transcription.

[1]  S. Steinberg,et al.  Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. , 1990, Annals of internal medicine.

[2]  H. Mitsuya,et al.  Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. , 1988, Science.

[3]  R. Koup,et al.  Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera , 1989, Journal of virology.

[4]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Walker,et al.  Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[7]  Q. Sattentau,et al.  Epitopes of the CD4 antigen and HIV infection. , 1986, Science.

[8]  H. Robinson,et al.  Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events , 1990, Journal of virology.

[9]  E. De Clercq,et al.  Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation , 1990, Antimicrobial Agents and Chemotherapy.

[10]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[11]  David Baltimore,et al.  A detailed model of reverse transcription and tests of crucial aspects , 1979, Cell.

[12]  R. Siliciano,et al.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation , 1988, Nature.

[13]  F. Brun-Vézinet,et al.  Isolation of a new human retrovirus from West African patients with AIDS. , 1986, Science.

[14]  D. Baltimore.  Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses , 1970, Nature.

[15]  L. Gritz,et al.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env , 1990, Journal of virology.

[16]  V. Knight,et al.  Biochemistry and clinical applications of ribavirin , 1986, Antimicrobial Agents and Chemotherapy.

[17]  J. Chermann,et al.  Inhibition of RNA-dependent DNA polymerases of AIDS and SAIDS retroviruses by HPA-23 (ammonium-21-tungsto-9-antimoniate) , 1985 .

[18]  S. Cohen,et al.  The enzymatic termination of polydeoxynucleotides by 2',3'-dideoxyadenosine triphosphate. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Levy,et al.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. , 1984, Science.

[20]  J. Adams,et al.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.

[21]  J. Maizel,et al.  Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Yamamoto,et al.  Infection of human T-lymphotropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): chronological studies of early events. , 1985, Virology.

[23]  B. Walker,et al.  HIV infection is blocked in vitro by recombinant soluble CD4 , 1988, Nature.

[24]  MartinS. Hirsch,et al.  INHIBITION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III IN VITRO BY PHOSPHONOFORMATE , 1985, The Lancet.

[25]  E. Gelmann,et al.  ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX , 1986, The Lancet.

[26]  A. Fauci,et al.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. , 1989, Science.

[27]  J. McCormick,et al.  RIBAVIRIN SUPPRESSES REPLICATION OF LYMPHADENOPATHY-ASSOCIATED VIRUS IN CULTURES OF HUMAN ADULT T LYMPHOCYTES , 1984, The Lancet.

[28]  H. Gendelman,et al.  Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus , 1986, The Journal of experimental medicine.

[29]  R. Dewar,et al.  Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport , 1989, Journal of virology.

[30]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[31]  B. Haynes,et al.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.

[32]  R. Schooley,et al.  RECOMBINANT HUMAN INTERFERON ALFA-A SUPPRESSES HTLV-III REPLICATION IN VITRO , 1985, The Lancet.

[33]  M. Somasundaran,et al.  Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytocidal infection. , 1988, Science.

[34]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[35]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[36]  P. Levine,et al.  Aetiology of AIDS—antibodies to human T-cell leukaemia virus (type III) in haemophiliacs , 1984, Nature.

[37]  M. Somasundaran,et al.  A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion , 1987, Journal of virology.

[38]  S. Matsushita,et al.  Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. , 1984, Science.

[39]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[40]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.